NRC FORM 591M PART 1 (10-2003) 10 CFR 2.201

U.S. NUCLEAR REGULATORY COMMISSION

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED:	2. NRC/REGIONAL OFFICE
Progressive Medical Imaging and Minimally Invasive Therapeutics, PLC **302 Center Avenue** **Bay City, MI 48708** REPORT 2006-001	**UNITED STATES** **NUCLEAR REGULATORY COMMISSION** **REGION III** **2443 WARRENVILLE ROAD, SUITE 210** **LISLE, IL 60532-4352**

3. DOCKET NUMBER(S)	4. LICENSEE NUMBER(S)	5. DATE(S) OF INSPECTION
030-36919	**21-32568-01**	**January 20, 2006**

LICENSEE:

The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:

☑ 1. Based on the inspection findings, no violations were identified.

☐ 2. Previous violation(s) closed.

☐ 3. The violation(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, NUREG-1600, to exercise discretion, were satisfied.

_____ Non-Cited Violation(s) was/were discussed involving the following requirement(s) and Corrective Action(s):

☐ 4. During this inspection certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11.

(Violations and Corrective Actions)

Licensee's Statement of Corrective Actions for Item 4, above.

I hereby state that, within 30 days, the actions described by me to the inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

Title	Printed Name	Signature	Date
LICENSEE'S REPRESENTATIVE			
NRC INSPECTOR	**Robert P. Hays**		**1/20/2006**

NRC FORM 591M PART 1 (10-2003)

NRC FORM 591M PART 3 (10-2003)
10 CFR 2.201

U.S. NUCLEAR REGULATORY COMMISSION

Docket File Information
SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE	2. NRC/REGIONAL OFFICE
Progressive Medical Imaging & M.I.T., PLC REPORT NUMBER(S) **2006-001**	**Region III**

3. DOCKET NUMBER(S)	4. LICENSE NUMBER(S)	5. DATE(S) OF INSPECTION
03036919	**21-32568-01**	**January 20, 2006**

6. INSPECTION PROCEDURES USED	7. INSPECTION FOCUS AREAS
87131	**03.01 - 03.07**

SUPPLEMENTAL INSPECTION INFORMATION

1. PROGRAM CODE(S)	2. PRIORITY	3. LICENSEE CONTACT	4. TELEPHONE NUMBER
02120	**3**	**Jeff Slowinski, CNMT**	**989/797-3000**

[X] Main Office Inspection — Next Inspection Date: **January 2009**

[ ] Field — **4200 Fashion Square Blvd., Saginaw, MI**

[ ] *Temporary Job Site*

PROGRAM SCOPE

The licensee was an out-patient medical facility located in Saginaw, Michigan, with authorization by the license to use any byproduct material permitted by 10 CFR 35.100, 35.200, and 35.300, not to exceed 1 curie. Licensed activities were initiated during September 2005 with one nuclear medicine technologist (NMT) routinely performing four diagnostic procedures/administrations per day for routine cardiac tests, bone scans, or other studies/scans as ordered. One I-131 dosage of 140 millicuries has been administered and other dosages less than 30 millcuries average one procedure per month. The licensee receives unit doses from a Saginaw, MI, nuclear pharmacy.

Performance Observations

During the inspection, licensee's NMTs demonstrated/discussed: (1) survey meter use and calibration; (2) package receiving and check-in procedures; (3) dose prep and safe use; (4) package wipe test counting; (5) dosimetry; (6) dose calibrator tests; (7) waste handling; (8) security of licensed material; (9) sealed source inventory; (10) radiation safety program audits; and (11) iodine-131 procedures and written procedures.